4-benzhydryloxypiperidine | CAS:58258-01-8

We serve 4-benzhydryloxypiperidine CAS:58258-01-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-benzhydryloxypiperidine

Chemical Name:4-benzhydryloxypiperidine
CAS.NO:58258-01-8
Synonyms:4-benzhydryloxypiperidine
4-(Benzhydryloxy)piperidine
4-(Diphenylmethoxy)piperidine
4-(diphenylmethyl)oxypiperidin
alfa,,alfa,-diphenyl-4-piperidinemethanol
Desalkyl Ebastine
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 383.5±42.0 °C at 760 mmHg
Melting Point 202-204℃
Molecular Formula C18H21NO
Molecular Weight 267.365
Flash Point 162.9±17.3 °C
 
Specification:
Appearance:Light brown solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Pharmaceutical intermediate.



Contact us for information like 4-benzhydryloxypiperidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Desalkyl Ebastine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-benzhydryloxypiperidine Use and application,4-(Diphenylmethoxy)piperidine technical grade,usp/ep/jp grade.


Related News: 2-(4-bromophenyl)-1H-benzimidazole manufacturer On 23 January, Chinese authorities confirmed this nCov can be transmitted between humans, with dozens of medical staff contracting the virus after treating infected patients.Methyl coumalate supplier However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period.3-(3-amino-2-hydroxyphenyl)benzoic acid vendor AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.“Inceptua Medicines Access is delighted to be selected as Onconova’s partner for the Pre-approval Access Program for rigosertib.